Table 7.4Options for adjuvant pharmacotherapy in later PD

Adjuvant therapy for later PDFirst-choice optionSymptom controlPossible risk of side effects
Motor complicationsOther adverse events
Dopamine agonists++
COMT inhibitors++
MAOB inhibitors++
Amantadine×NS
Apomorphine×+
+++

Good degree of symptom control.

++

Moderate degree of symptom control.

+

Limited degree of symptom control.

Evidence of increased motor complications/other adverse events.

Evidence of reduced motor complications/other adverse events.

NS = Non-significant result.

From: 7, Symptomatic pharmacological therapy in Parkinson’s disease

Cover of Parkinson's Disease
Parkinson's Disease: National Clinical Guideline for Diagnosis and Management in Primary and Secondary Care.
NICE Clinical Guidelines, No. 35.
National Collaborating Centre for Chronic Conditions (UK).
Copyright © 2006, Royal College of Physicians of London.

All rights reserved. No part of this publication may be reproduced in any form (including photocopying or storing it in any medium by electronic means and whether or not transiently or incidentally to some other use of this publication) without the written permission of the copyright owner. Applications for the copyright owner’s written permission to reproduce any part of this publication should be addressed to the publisher.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.